Anesthesia, Anesthesia; Functional, Anesthesia, Local, Opioid Use, Pain, Postoperative
Conditions
Brief summary
This study evaluates differences in how administering liposomal bupivacaine via two different methods affects postoperative pain control in laparoscopic abdominal surgery patients. Half the participants will receive liposomal bupivacaine via a transverses abdominis plane block while the other half will receive liposomal bupivacaine via local infiltration.
Detailed description
Liposomal bupivacaine is a newer formulation of a local anesthetic that is commonly used for local infiltration, peripheral nerve blocks, and neuraxial anesthesia. This new formulation allows the effects of bupivacaine to last up to 72 hours as it is slowly released from a liposome. It is FDA approved for local infiltration and has recently been approved for interscalene blocks. A transversus abdominis plane block is a fascial plane block that is performed routinely for postoperative pain relief for some abdominal incisions. It is performed by placing local anesthetic between the internal oblique and transverses abdominis muscle planes where it will provide analgesia to several dermatomes of the abdomen in hopes of improving postoperative pain relief and reducing postoperative opioid requirement.
Interventions
Liposomal bupivacaine
Sponsors
University of Washington
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Intervention model description
Unblinded randomized trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients scheduled for elective laparoscopic colorectal surgery at UWMC requiring inpatient stay
Exclusion criteria
* Patients on chronic pain mediations equaling or exceeding \> 25 morphine daily equivalents * Patients allergic to bupivacaine * Patients with ASA status IV, V, or VI * Patients unable to consent * Patients that are pregnant * Patients that are incarcerated * Patients receiving procedures in addition to laparoscopic colorectal procedure * Patients on systemic anticoagulation precluding them from regional blocks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 24 hour post operative opioid consumption | 24 hours postoperative | Listed in morphine daily equivalents. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 12 hour post operative opioid consumption | 12 hours postoperative | Listed in morphine daily equivalents |
| 48 hour post operative opioid consumption | 48 hours postoperative | Listed in morphine daily equivalents |
| Pain intensity at 12 hours post operative | 12 hours | Self reported pain intensity by visual analog scale scored 0-10 (0 = no pain; 10 = worst pain imaginable) |
| Pain intensity at 24 hours post operative | 24 hours | Self reported pain intensity by visual analog scale scored 0-10 (0 = no pain; 10 = worst pain imaginable) |
| Hospital length of stay | Until end of hospital stay, typically 3 days | How long the patient requires their inpatient stay measured in days. |
Contacts
Primary ContactAlan Chang, MD
Outcome results
None listed